Olema Pharmaceuticals, Inc. (OLMA)

Market Cap	549.64M
Revenue (ttm)	n/a
Net Income (ttm)	-96.66M
Shares Out	55.91M
EPS (ttm)	-2.14
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,281,746
Open	9.87
Previous Close	10.15
Day's Range	9.46 - 10.05
52-Week Range	4.26 - 17.79
Beta	2.11
Analysts	Strong Buy
Price Target	21.80 (+121.77%)
Earnings Date	May 7, 2024

About OLMA

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 19, 2020
• Employees: 74
• Stock Exchange: NASDAQ
• Ticker Symbol: OLMA

Analyst Forecast

According to 5 analysts, the average rating for OLMA stock is "Strong Buy." The 12-month stock price forecast is $21.8, which is an increase of 121.77% from the latest price.

Price Target

$21.8

(121.77% upside)

Analyst Consensus: Strong Buy